Saratoga Health & Biotechnology A holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Saratoga Health & Biotechnology Portfolio Fund Class A SHPAX
- NAV / 1-Day Return $23.56 / +1.90 %
- Fund Size $11.4M
- Adjusted Expense Ratio 3.000%
- Net Expense Ratio 3.000%
- Fee Level: Distribution High
- Share Class Type Front Load
- Morningstar Category Health
- Equity Style Box (Funds) Mid Value
- Minimum Initial Investment $2,500
- Investment Status Open
- TTM Yield 0.00%
- Turnover Ratio 22%
Morningstar’s Analysis SHPAX
Will SHPAX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Jazz Pharmaceuticals PLC | 5.92 | 687,114 | Healthcare |
Amgen Inc | 5.81 | 673,622 | Healthcare |
McKesson Corp | 5.27 | 611,756 | Healthcare |
Cardinal Health Inc | 5.11 | 593,354 | Healthcare |
United Therapeutics Corp | 5.10 | 592,041 | Healthcare |
Cencora Inc | 4.69 | 544,619 | Healthcare |
Regeneron Pharmaceuticals Inc | 4.61 | 535,384 | Healthcare |
Exelixis Inc | 4.45 | 516,075 | Healthcare |
Johnson & Johnson | 4.17 | 483,847 | Healthcare |
Novartis AG ADR | 4.12 | 477,468 | Healthcare |
United States